HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (12) Citing Articles via Google Scholar Google Scholar Articles by Marceau, G. Articles by Laurichesse, H. Search for Related Content PubMed PubMed Citation Articles by Marceau, G. Articles by Laurichesse, H. Related Collections General Clinical Chemistry Clinical Immunology Drug Monitoring and Toxicology

Frequency, Risk Factors, and Outcome of Hyperlactatemia in HIV-positive Persons: Implications for the Management of Treated Patients

Departments of
¹ Biochemistry,
² Infectious Diseases and Tropical Medicine,
³ Medical Information, and
⁴ Virology, Faculty of Medicine, University Hospital of Clermont-Ferrand, 63000 Clermont-Ferrand, France.

^aAddress correspondence to this author at: Laboratoire de Biochimie Médicale, Faculté de Médecine, 28, Place Henri Dunant, BP. 38, 63000 Clermont-Ferrand; France. Fax 33-4-7327-6132; e-mail visapin{at}courrier.u-clermont1.fr.

Background: The nucleoside reverse transcriptase inhibitors used for the treatment of HIV-positive persons are now clearly associated with metabolic disorders. We determined the prevalence of and risk factors for hyperlactatemia in HIV-positive persons to assess the relevance of lactate venous blood concentrations during antiretroviral therapy.

Methods: We conducted a prospective cross-sectional study of venous lactate determinations with 282 consecutive HIV-positive persons who, in addition to a physical examination, had blood samples taken every 3–4 months for routine biochemical, immunologic, and viral assessment. The frequencies of hyperlactatemia and lactic acidosis were determined, and the risk factors were analyzed by a multivariate logistic regression model. The effect of modification of antiretroviral therapy in patients with moderate hyperlactatemia was also assessed.

Results: From 782 blood lactate determinations, we identified 65 (23%) patients with moderate hyperlactatemia and 5 (1.8%) with lactate concentrations >5 mmol/L (2 with severe lactic acidosis; 0.7%). Older age, drug regimens containing stavudine [adjusted odds ratio (OR) = 2.5] or a combination of stavudine-didanosine (adjusted OR = 3.1), and the use of buprenorphine (adjusted OR = 14.7) were independent predictors of hyperlactatemia. Among 65 patients with moderate hyperlactatemia, 39 did not have their treatments changed, and 26 had a new combination therapy that was associated with a clinical improvement and a more pronounced decrease in lactate (-1.66 vs -0.99 mmol/L; P <0.05).

Conclusions: Chronic compensated and moderate hyperlactatemia was common in our population study. Measurement of lactate, under standardized conditions, may be useful in optimizing management of HIV-positive persons on antiretroviral therapy.

The following articles in journals at HighWire Press have cited this article:

				M. Prod'homme, C. Rochon, M. Balage, H. Laurichesse, I. Tauveron, C. Champredon, P. Thieblot, J. Beytout, and J. Grizard Whole body leucine flux in HIV-infected patients treated with or without protease inhibitors Am J Physiol Endocrinol Metab, April 1, 2006; 290(4): E685 - E693. [Abstract] [Full Text] [PDF]

				P. J. Fall and H. M. Szerlip Lactic Acidosis: From Sour Milk to Septic Shock J Intensive Care Med, September 1, 2005; 20(5): 255 - 271. [Abstract] [PDF]